Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics

The potential for μ-opioid receptor agonists to be anti-emetic in humans: a review of clinical data

(2009) KEVIN D. JOHNSTON   ACTA ANAESTHESIOLOGICA SCANDINAVICA

Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression

(2009) Emmanuel S. Onaivi et al.   Annals of the New York Academy of Sciences

Antiemetic control: toward a new standard of care for emetogenic chemotherapy

(2009) Rudolph M Navari   EXPERT OPINION ON PHARMACOTHERAPY

A Randomized, Double-blind, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron plus Dexamethasone Injection for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting

(2009) C. L. Ho et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Whole brain radiotherapy with radiosensitizer for brain metastases

(2009) Gustavo Viani et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

(2009) Steven M Grunberg et al.   LANCET ONCOLOGY

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

(2009) Mitsue Saito et al.   LANCET ONCOLOGY

Chemotherapy-Induced Nausea and Vomiting

(2008) Lisa Lohr   CANCER JOURNAL

Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response

(2008) Elena Massa et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Chemotherapy and cancer related nausea and vomiting

(2008) David Warr   Current Oncology

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

(2008) P. A. Fasching et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Evidence-Based Recommendations for Cancer Nausea and Vomiting

(2008) Arash Naeim et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE

Investigation ofHTR3Cmutations for association with 5HT3receptor antagonist anti-emetic efficacy

(2008) Michael B Ward et al.   PHARMACOGENOMICS

Serotonin type 3 receptor genes:HTR3A, B, C, D, E

(2008) Beate Niesler et al.   PHARMACOGENOMICS

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

(2008) Steven M. Grunberg et al.   SUPPORTIVE CARE IN CANCER

Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy

(2008) Maurizio Musso et al.   SUPPORTIVE CARE IN CANCER